US FDA grants priority review to Roche’s Tecentriq as adjuvant treatment for non-small cell lung… EP News Bureau Aug 3, 2021 Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the adjuvant lung cancer setting…
